ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings

August 05, 2025 at 23:07 PM EDT

ICUI Cover Image

Medical device company ICU Medical (NASDAQ: ICUI) will be announcing earnings results this Thursday after market close. Here’s what to expect.

ICU Medical beat analysts’ revenue expectations by 5.7% last quarter, reporting revenues of $599.5 million, up 5.8% year on year. It was an incredible quarter for the company, with a solid beat of analysts’ EPS estimates.

Is ICU Medical a buy or sell going into earnings? Read our full analysis here, it’s free.

This quarter, analysts are expecting ICU Medical’s revenue to decline 9.5% year on year to $539.7 million, a reversal from the 8.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.50 per share.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ICU Medical has missed Wall Street’s revenue estimates twice over the last two years.

Looking at ICU Medical’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Merit Medical Systems delivered year-on-year revenue growth of 13.2%, beating analysts’ expectations by 2.4%, and Penumbra reported revenues up 13.4%, topping estimates by 3.7%. Merit Medical Systems traded up 2.4% following the results while Penumbra was also up 11.9%.

Read our full analysis of Merit Medical Systems’s results here and Penumbra’s results here.

Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. ICU Medical’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $186.20 (compared to the current share price of $129.02).

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

About Us

Additional Information

Website & Technical Help

ICU Medical (ICUI) Reports Q2: Everything You Need To Know Ahead Of Earnings

More News